Insider and congress filings

Labcorp Holdings Inc. (LH)

NYSE · Healthcare · 313 insider transactions · 81 congress trades · last filed 2 months agoS&P 500

16
Open-market insider filings shown
2d
Median delay on the insider filings, in business days
within the two business day rule
0 buys·16 sells
Purchases and sales in the filings shown
Get a push when an insider at Labcorp Holdings Inc. trades.

Free on iOS and Android.

About Labcorp Holdings Inc.

from the company's filings and listing, as of Oct 22, 2026
Exchange
NYSE
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Chief executive
Adam H. Schechter
Employees
71,000
Listed since
Mar 29, 1990
Market value
$26.3B
Price to earnings (12 mo)
26.6
Net income per share, as reported (12 mo)
$12.27
Dividend yield
0.89%

www.labcorp.com

Earnings

6 reported quarters · next on Oct 28, 2026
QuarterEPSEPS expectedRevenueRevenue expectedResult
Q2 FY2026reported Jul 30, 2026$4.99$4.78$3.7B$3.7BEPS beatRevenue in line
Q1 FY2026reported Apr 30, 2026$4.25$4.11$3.5B$3.5BEPS beatRevenue in line
Q4 FY2025reported Feb 17, 2026$4.07$3.95$3.5B$3.6BEPS beatRevenue in line
Q3 FY2025reported Oct 28, 2025$4.18$4.13$3.6B$3.6BEPS in lineRevenue in line
Q2 FY2025reported Jul 24, 2025$4.35$4.17$3.5B$3.5BEPS beatRevenue in line
Q1 FY2025reported Apr 29, 2025$3.84$3.74$3.3B$3.4BEPS beatRevenue miss

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

Executive pay

as filed for fiscal 2025 · proxy filed Apr 10, 2026
ExecutiveSalaryStock awardsOtherTotal
Adam H. SchechterPresident and Chief Executive Officer$1.4M$11.4M$5.5M$18.3M
Julia A. WangExecutive Vice President and Chief Financial Officer$738K$2.7M$1.6M$5.0M
Brian J. CaveneyExecutive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer$748K$2.3M$1.3M$4.4M
Megan D. BaileyExecutive Vice President and President, Central Laboratories and International$569K$1.3M$890K$2.7M

The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. 1 executive who has since left the company is named in that filing and not shown here. Read the filing

Institutional holders

13F positions as of Jun 30, 2026
HolderValueSharesShares vs prior qtr% of shares out
BlackRock, Inc.$1.8B6,574,261+2.0%8.05%
Vanguard Capital Management LLC$1.5B5,362,254-0.3%6.56%
Victory Capital Management Inc$1.4B4,837,573+4.5%5.92%
State Street Corp$1.1B3,907,656+1.2%4.75%
Vanguard Portfolio Management LLC$1.0B3,678,798-0.1%4.50%
Boston Partners$854.2M3,051,690+28.8%3.74%
Allspring Global Investments Holdings, LLC$635.0M2,236,957+0.5%2.74%
Geode Capital Management, LLC$610.4M2,188,890+0.1%2.68%
Select Equity Group, L.P.$554.9M1,981,948-8.9%2.43%
FMR LLC$533.4M1,904,870+47.8%2.33%
Morgan Stanley$450.6M1,609,447+7.4%1.97%
Dimensional Fund Advisors LP$382.8M1,367,166+2.6%1.67%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

Know when the next LH filing is reported.

GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.

Open-market insider trades

16 filings shown · newest filing first
InsiderActionSharesPriceValueTrade dateDelay
(business days)
Kerrii B. AndersonDirectorSold · scheduled3,000$318.02$954KAug 17, 2026filed Aug 18, 20261d
Adam H. SchechterPresident & CEOSold · scheduled4,669$320.37$1.5MAug 11, 2026filed Aug 12, 20261d
Amy B. SummyEVP, Chief Marketing OfficerSold924$306.74$283KAug 4, 2026filed Aug 6, 20262d
Peter J. WilkinsonSVP, Chief Accounting OfficerSold · 2 lines1,420$309.23$439KAug 3, 2026filed Aug 5, 20262d
Bryan T. VaughnEVP and President, DiagnosticsSold · scheduled234$286.19$67KJul 2, 2026filed Jul 6, 20261d
Kathryn W. KyleEVP, Chief Legal OfficerSold · scheduled92$286.19$26KJul 2, 2026filed Jul 6, 20261d
Kathryn W. KyleEVP, Chief Legal OfficerSold · scheduled762$263.89$201KJun 8, 2026filed Jun 10, 20262d
Adam H. SchechterPresident & CEOSold · scheduled5,903$254.50$1.5MMay 11, 2026filed May 13, 20262d
Jonathan C. MeltzerEVP, OperationsSold · scheduled839$267.05$224KMar 27, 2026filed Mar 30, 20261d
Peter J. WilkinsonSVP, Chief Accounting OfficerSold · scheduled1,633$267.05$436KMar 27, 2026filed Mar 30, 20261d
Adam H. SchechterPresident & CEOSold8,705$279.96$2.4MMar 3, 2026filed Mar 5, 20262d
Sandra D. van der VaartEVP, Corporate AffairsSold548$284.91$156KFeb 27, 2026filed Mar 3, 20262d
Brian J. CaveneyEVP, Pres of ED, CMO & CSOSold1,500$286.31$429KFeb 24, 2026filed Feb 26, 20262d
Peter J. WilkinsonSVP, Chief Accounting OfficerSold · scheduled666$277.94$185KFeb 19, 2026filed Feb 23, 20262d
Jonathan C. MeltzerEVP, OperationsSold · scheduled87$290.42$25KFeb 12, 2026filed Feb 13, 20261d
Adam H. SchechterPresident & CEOSold · scheduled5,273$284.38$1.5MFeb 11, 2026filed Feb 13, 20262d

One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.

Other Form 4 activity (20)
InsiderEventSharesDate
Brian J. CaveneyEVP, Pres of BLS, CMO & CSOStock award3,000Sep 1, 2026
Bryan T. VaughnEVP and President, DiagnosticsStock award1,500Sep 1, 2026
Jonathan C. MeltzerEVP, COOStock award900Sep 1, 2026
Akinbolade OyegunwaEVP, CIO & CTOStock award750Sep 1, 2026
Peter J. WilkinsonSVP, Chief Accounting OfficerOption exercise1,338Aug 3, 2026
Bryan T. VaughnEVP and President, DiagnosticsTax withholding93Jul 1, 2026
Bryan T. VaughnEVP and President, DiagnosticsOption exercise327Jul 1, 2026
Kathryn W. KyleEVP, Chief Legal OfficerTax withholding73Jul 1, 2026
Kathryn W. KyleEVP, Chief Legal OfficerOption exercise256Jul 1, 2026
Megan D. BaileyEVP, Pres, Central Labs & IntlTax withholding481Mar 26, 2026
Megan D. BaileyEVP, Pres, Central Labs & IntlStock award1,184Mar 26, 2026
Kathryn W. KyleEVP, Chief Legal OfficerTax withholding451Mar 26, 2026
Kathryn W. KyleEVP, Chief Legal OfficerStock award1,584Mar 26, 2026
Jonathan C. MeltzerEVP, OperationsTax withholding711Mar 26, 2026
Jonathan C. MeltzerEVP, OperationsStock award2,388Mar 26, 2026
Akinbolade OyegunwaEVP, CIO & CTOTax withholding382Mar 26, 2026
Akinbolade OyegunwaEVP, CIO & CTOStock award1,340Mar 26, 2026
Amy B. SummyEVP, Chief Marketing OfficerTax withholding1,836Mar 26, 2026
Amy B. SummyEVP, Chief Marketing OfficerStock award3,994Mar 26, 2026
Sandra D. van der VaartEVP, Corporate AffairsTax withholding2,722Mar 26, 2026

Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.

Congress trades in LH

20 disclosures of 81 on record · median 16d of the 45 allowed

Since the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 24, 2026), not the member's result. Not investment advice.

MemberTypeActionAmount disclosedStock since the tradeTrade dateDisclosedDelay
April McClain DelaneyDependent childStockSale$100,001 - $250,000-2.6%After the saleS&P 500 -0.8% · -1.8 pts vs S&P 500Aug 25, 2026Sep 9, 202615d
April McClain DelaneyDependent childStockSale$1,001 - $15,000+4.8%After the saleS&P 500 -1.3% · +6.1 pts vs S&P 500Aug 5, 2026Sep 9, 202635d
April McClain DelaneyDependent childStockSale$1,001 - $15,000+3.9%After the saleS&P 500 -1.1% · +5.0 pts vs S&P 500Aug 6, 2026Sep 9, 202634d
April McClain DelaneyDependent childStockSale$1,001 - $15,000+3.1%After the saleS&P 500 -1.7% · +4.8 pts vs S&P 500Aug 7, 2026Sep 9, 202633d
Alan ArmstrongSelfStockPurchase$1,001 - $15,000+24.5%S&P 500 +19.8% · +4.7 pts vs S&P 500Mar 27, 2026Jul 21, 2026116d
Ro KhannaStockSale$1,001 - $15,000+17.5%After the saleS&P 500 +1.7% · +15.8 pts vs S&P 500Jun 30, 2026Jul 6, 20266d
Ro KhannaStockPurchase$1,001 - $15,000+31.4%S&P 500 +2.8% · +28.6 pts vs S&P 500May 15, 2026Jun 9, 202625d
April McClain DelaneyDependent childStockPurchase$1,001 - $15,000+19.1%S&P 500 +10.7% · +8.4 pts vs S&P 500Feb 4, 2026Mar 10, 202634d
April McClain DelaneyDependent childStockPurchase$1,001 - $15,000+13.5%S&P 500 +9.8% · +3.7 pts vs S&P 500Feb 11, 2026Mar 10, 202627d
Ro KhannaStockSale$1,001 - $15,000+31.4%After the saleS&P 500 +9.3% · +22.1 pts vs S&P 500Jan 12, 2026Feb 6, 202625d
Ro KhannaStockSale$1,001 - $15,000+21.9%After the saleS&P 500 +9.5% · +12.5 pts vs S&P 500Jan 29, 2026Feb 6, 20268d
April McClain DelaneyDependent childStockPurchase$1,001 - $15,000+22.7%S&P 500 +9.2% · +13.5 pts vs S&P 500Jan 28, 2026Feb 2, 20265d
April McClain DelaneyDependent childStockPurchase$1,001 - $15,000+25.9%S&P 500 +14.1% · +11.7 pts vs S&P 500Nov 17, 2025Dec 8, 202521d
Ro KhannaStockSale$1,001 - $15,000+19.3%After the saleS&P 500 +10.9% · +8.5 pts vs S&P 500Oct 27, 2025Nov 6, 202510d
April McClain DelaneyDependent childStockPurchase$1,001 - $15,000+32.6%S&P 500 +10.5% · +22.0 pts vs S&P 500Oct 29, 2025Nov 4, 20256d
April McClain DelaneyDependent childStockPurchase$1,001 - $15,000+29.5%S&P 500 +11.4% · +18.1 pts vs S&P 500Oct 31, 2025Nov 4, 20254d
Ro KhannaStockSale$1,001 - $15,000+26.0%After the saleS&P 500 +26.2% · -0.2 pts vs S&P 500Jun 23, 2025Jul 9, 202516d
Ro KhannaStockSale$1,001 - $15,000+26.2%After the saleS&P 500 +23.2% · +3.0 pts vs S&P 500Jun 27, 2025Jul 9, 202512d
Ro KhannaStockPurchase$1,001 - $15,000+33.2%S&P 500 +29.3% · +3.9 pts vs S&P 500May 28, 2025Jun 10, 202513d
Robert BresnahanStockPurchase$1,001 - $15,000+33.6%S&P 500 +28.7% · +4.9 pts vs S&P 500May 15, 2025May 31, 202516d

Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.

A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.

Every Congress trade in LH, filterable by party, chamber, type and account.

Members of Congress reporting a position

3 members · estimate, as of Oct 21, 2026

3 members report a position (estimated). The largest estimated position is in the $50,001 - $100,000 band.

MemberParty, chamberEstimated positionShare of their portfolio
J. French HillRepublican · House$50,001 - $100,0000.6%
Gilbert Ray Cisneros, Jr.Democrat · House$1,001 - $15,000<0.1%
Robert BresnahanRepublican · House$1,001 - $15,0000.1%

Estimate, as of Oct 21, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.

Questions

Are insiders buying or selling LH?

Across the 16 most recent open-market filings shown here, 0 were purchases and 16 were sales. 11 were scheduled in advance under a Rule 10b5-1 plan.

Which members of Congress have traded LH?

April McClain Delaney, Alan Armstrong, Ro Khanna and Robert Bresnahan disclosed LH transactions in the filings shown here.

Which members of Congress hold LH?

3 members of Congress report a position in LH in the estimate we hold as of Oct 21, 2026. The estimated positions belong to J. French Hill, Gilbert Ray Cisneros, Jr. and Robert Bresnahan. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.

Is LH in the S&P 500 or the Nasdaq 100?

Labcorp Holdings Inc. is a current member of the S&P 500, per the membership list we hold as of Oct 26, 2026. Current members of either index get a page here whatever their filing history.

How quickly are LH trades disclosed?

Insider filings on this page reached the public a median of 2 business days after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 16 days, against the 45 the STOCK Act allows.

How to read a Form 4

A DECISION THE INSIDER MADE

POpen-market purchase. Bought with their own money at the market price.
SOpen-market sale. Sold on the market. A sale marked scheduled was set up in advance under a Rule 10b5-1 plan, often months before.

COMPENSATION PLUMBING

AStock award. Granted as pay, not bought.
MOption exercise. Converting options already held into shares.
FTax withholding. Shares handed back to the company to pay the tax on a grant.
GGift. Given away, with no money changing hands.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

Data as of Oct 26, 2026.

Related companies

traded by the same members

See every company we track